Practical Dermatology

Practical Dermatology A monthly publication that provides coverage of medical care, cosmetic advancements, and practice management for clinicians in the field.
(7)

www.practicaldermatology.com Practical Dermatology delivers real-world medical, cosmetic, and practice management advice for dermatologists and dermatology physician assistants. Readers recognize that Practical Dermatology’s unique editorial style cuts to the heart of the issues with expert opinions, timely coverage, clinical summaries, and high-quality supportive graphics. Whether readers are loo

king for insights on the latest aesthetic interventions, tips to manage difficult medical conditions, or advice to grow their practice, they’ll find reliable answers in Practical Dermatology.

📣🩺 The December 2024 issue of Practical Dermatology takes a look back at the trends from this year and peeks into 2025 w...
12/17/2024

📣🩺 The December 2024 issue of Practical Dermatology takes a look back at the trends from this year and peeks into 2025 with what's ahead. Dive in! 📰

📖 IN THE ISSUE:
💡2024 in Review – Top dermatology trends
💡 Scar-free Cyst Removal – Check out this minimally invasive technique
💡 JAK Inhibitors in Hidradenitis Suppurativa – An in-depth systematic review

ALSO INSIDE:
✅ Reflections on mentorship and fulfillment from Dr. Peter Lio
✅ Case report: Adnexal clear cell with comedonecrosis
✅ Strategies for maximizing practice valuation: A Q&A with Dana Jacoby
✅ Treatment insights for

Read the issue here ➡️ https://bit.ly/3DfM5Cr

As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.

📢 💊 TAPINAROF APPROVED FOR AD: The FDA has approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an ad...
12/16/2024

📢 💊 TAPINAROF APPROVED FOR AD: The FDA has approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older, Organon announced.

Read more ➡️ https://bit.ly/4iH6LUa

The US Food and Drug Administration (FDA) approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical ...

🔬💼  FUNDING UPDATE: Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be use...
12/13/2024

🔬💼 FUNDING UPDATE: Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be used to fund the ongoing clinical development of the company’s lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL).💊

📖 Read more: https://bit.ly/41w7NMp

Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be used to fund the ongoing clinical development of the comp...

📚 🔎 📣 MAKING PROGRESS: A new analysis of melasma clinical trials shows significant gender and racial representation prog...
12/12/2024

📚 🔎 📣 MAKING PROGRESS: A new analysis of melasma clinical trials shows significant gender and racial representation progress, with potential implications for research inclusivity in other conditions.

Read the story ➡️ https://bit.ly/41sF0IJ

A new analysis of melasma clinical trials indicates progress toward inclusivity, with broad gender, racial, and Fitzpatrick skin type (FST) representation...

🌏 🏥 INCREASING GLOBAL ACCESS: In this Dermwire TV Extra, Esther Freeman, MD, PhD, Associate Professor of Dermatology at ...
12/11/2024

🌏 🏥 INCREASING GLOBAL ACCESS: In this Dermwire TV Extra, Esther Freeman, MD, PhD, Associate Professor of Dermatology at Harvard Medical School and Director of Global Health Dermatology at Massachusetts General Hospital, talks with Practical Dermatology about her work as principal investigator for the Global Access to Skin Health Observatory study. Dr. Freeman also serves as Vice Chair of the International Foundation of Dermatology with The International League of Dermatological Societies (ILDS), where she leads efforts to expand global access to skin health.

Watch the video 📺 https://bit.ly/3Bxr3OT

Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the Interna…

📈 🔬 GROWTH IN ATOPIC DERMATITIS: Projected to hit $22.6 billion by 2031, the global atopic dermatitis market is being dr...
12/10/2024

📈 🔬 GROWTH IN ATOPIC DERMATITIS: Projected to hit $22.6 billion by 2031, the global atopic dermatitis market is being driven in part by the uptake of biologics, investments in infrastructure, and the proliferation of patient-centric care, according to a new report. The North American market remains the leader, but the Asia-Pacific market has emerged as the growth hotspot.

Read more 👉 https://bit.ly/4ikMvHw

The atopic dermatitis (AD) market is forecasted to grow from $5.3 billion in 2021 to $22.6 billion by 2031, with a compound annual growth rate (CAGR) of 1...

🎙️ 👨‍⚖️ C-SUITE CHAT: Ed Esquenazi, PhD, Founder and CEO of health and performance company Terns, discusses the after-su...
12/09/2024

🎙️ 👨‍⚖️ C-SUITE CHAT: Ed Esquenazi, PhD, Founder and CEO of health and performance company Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.

Watch the video 📺 ➡️ https://bit.ly/3CZ3xL4

Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to com…

💼 🎙️ C-SUTE CHAT: David Domzalski, CEO and President of VYNE Therapeutics Inc., talks about the challenges of treating v...
12/06/2024

💼 🎙️ C-SUTE CHAT: David Domzalski, CEO and President of VYNE Therapeutics Inc., talks about the challenges of treating vitiligo and how his company is working to address those challenges.

Watch the video ➡️ https://bit.ly/4fbWAUE

David Domzalski, CEO and President of Vyne Therapeutics, discusses what makes vitiligo difficult to treat and how his company is working to address those …

💡🔬 PDT IN PRACTICE: In this new installment of the PDT In Practice video series, dermatologist Todd Schlesinger, MD, rev...
12/05/2024

💡🔬 PDT IN PRACTICE: In this new installment of the PDT In Practice video series, dermatologist Todd Schlesinger, MD, reveals how he incorporated photodynamic therapy (PDT) into his practice and explains some of the strategies he utilized to increase patient access to the treatment.

Watch the video ➡️ https://bit.ly/3VpeZpT

Dr. Todd Schlesinger described how he implemented photodynamic therapy in his practice and the strategies he utilized to increase patient access to it.

💡 🔬 PDT IN PRACTICE: In this new installment of PDT In Practice, dermatologist Todd Schlesinger, MD, reveals how he inco...
12/05/2024

💡 🔬 PDT IN PRACTICE: In this new installment of PDT In Practice, dermatologist Todd Schlesinger, MD, reveals how he incorporated photodynamic therapy (PDT) into his practice and explains some of the strategies he utilized to increase patient access to the treatment.

Watch the video 📺 ➡️ https://bit.ly/3VpeZpT

Dr. Todd Schlesinger described how he implemented photodynamic therapy in his practice and the strategies he utilized to increase patient access to it.

📊 📝 🔬 OLYMPIA 1 TRIAL: Nemolizumab may hold promise for prurigo nodularis treatment, according to results from the OLYMP...
12/04/2024

📊 📝 🔬 OLYMPIA 1 TRIAL: Nemolizumab may hold promise for prurigo nodularis treatment, according to results from the OLYMPIA 1 trial. The phase 3 data showed nemolizumab linked with significant improvements in itch and skin lesions.

Read the story ➡️ https://bit.ly/3B9dGED

Results from a multicenter phase 3 clinical trial indicated that nemolizumab monotherapy significantly reduces pruritus and nodular lesions in adults with...

📣 🔬  PSORIASIS NEWS: Tremfya (guselkumab) may soon be able address gaps in care in pediatric patients with psoriasis or ...
12/03/2024

📣 🔬 PSORIASIS NEWS: Tremfya (guselkumab) may soon be able address gaps in care in pediatric patients with psoriasis or juvenile psoriatic arthritis. Johnson & Johnson has filed for FDA approval for its use in treating childhood plaque psoriasis and juvenile psoriatic arthritis.

Read more ➡️ https://bit.ly/3Zh5uKA

Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremf...

🌟 🏆 ADVANCING YOUR DERM CAREER: Andrew M. Mastro, M.S., PA-C shares strategies for setting yearly goals to build a succe...
12/02/2024

🌟 🏆 ADVANCING YOUR DERM CAREER: Andrew M. Mastro, M.S., PA-C shares strategies for setting yearly goals to build a successful dermatology career, discussing his approach and offering a roadmap for PAs and professionals to drive growth, stay motivated, and build long-term success. This video was recorded at the 2024 Society of Dermatology Physician Associates (SDPA) annual meeting in Las Vegas.

Watch the video ➡️ https://bit.ly/3V0ySmH

Andrew M. Mastro, M.S., PA-C shares strategies for setting yearly goals to build a successful dermatology career.

👨‍🔬 ❤️ PASSION FOR TREATING AD: Dr. Matthew Zirwas brought his expertise and passion for treating atopic dermatitis (AD)...
11/29/2024

👨‍🔬 ❤️ PASSION FOR TREATING AD: Dr. Matthew Zirwas brought his expertise and passion for treating atopic dermatitis (AD) to the 2024 Society of Dermatology Physician Associates (SDPA) annual meeting, sharing innovative approaches and tips for improving patient-centric care.

Watch the video👉 https://bit.ly/49bQAtt

At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. He provides a passionate overview of his lec…

📺 DERMWIRE TV EXTRA: Dr. Emily Ruiz, a Mohs surgeon at Brigham and Women's Hospital, and a cutaneous oncologist at Dana-...
11/27/2024

📺 DERMWIRE TV EXTRA: Dr. Emily Ruiz, a Mohs surgeon at Brigham and Women's Hospital, and a cutaneous oncologist at Dana-Farber Cancer Institute, highlights the importance of gene expression profile (GEP) testing in squamous cell carcinoma management, particularly for patients with skin of color.

Watch here 👉 https://bit.ly/3ZlQYlO

Emily Ruiz, MD, MPH, FAAD, a Mohs surgeon at Brigham and Women's Hospital and cutaneous oncologist at Dana-Farber Cancer Institute, discusses her recent F…

📊 🔎 UPDATES IN ATOPIC DERMATITIS: New research in atopic dermatitis (AD) is focusing on anti-OX40 ligand antibodies, aim...
11/26/2024

📊 🔎 UPDATES IN ATOPIC DERMATITIS: New research in atopic dermatitis (AD) is focusing on anti-OX40 ligand antibodies, aiming to modulate key inflammatory pathways. Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, elaborates on amlitelimab in adult patients with moderate-to-severe atopic dermatitis, and how this novel approach could add to treatment options for patients with moderate to severe AD.

Watch the video ➡️ https://bit.ly/3Om16EP

Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discuss…

🎤 👩‍🔬 SPOTLIGHT ON VULVOVAGINAL DERM: Audrey Rutherford MD's path to specializing in vulvovaginal dermatology was a draw...
11/25/2024

🎤 👩‍🔬 SPOTLIGHT ON VULVOVAGINAL DERM: Audrey Rutherford MD's path to specializing in vulvovaginal dermatology was a draw at the 2024 Society of Dermatology Physician Associates (SDPA) annual meeting in Las Vegas. Dr. Rutherford emphasized the importance of addressing these sensitive and under-discussed conditions in paving the way for better patient outcomes.

Watch the video 👉 https://bit.ly/493K7Rb

At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Audrey Rutherford, MD. Dr. Rutherford shares how she got started…

📣 📺 DERMWIRE TV: In this week's edition of DermWire TV, the FDA approves BIMZELX® (bimekizumab-bkzx) HCP for the treatme...
11/25/2024

📣 📺 DERMWIRE TV: In this week's edition of DermWire TV, the FDA approves BIMZELX® (bimekizumab-bkzx) HCP for the treatment of moderate to severe hidradenitis suppurativa; the Agency also agreed to review the resubmission of DUPIXENT® (dupilumab) HCP for the treatment of CSU; and the president of Merz Aesthetics, North America, discusses trends in the aesthetic market.

Watch the full report here ➡️ https://practicaldermatology.com/series/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/

In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of …

Address

1008 Upper Gulph Road
Wayne, PA
19087

Alerts

Be the first to know and let us send you an email when Practical Dermatology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Practical Dermatology:

Videos

Share